4 results about "Recombinant interferon" patented technology

The invention relates to canine recombinant interferon-alpha3 and application thereof, and relates to the technical field of biological products. The amino acid sequence of the canine recombinant interferon-alpha3 disclosed by the invention is as shown in SEQ ID NO. 2. The nucleotide sequence of the nucleic acid molecule for coding the canine recombinant interferon-alpha3 is as shown in SEQ ID NO. 1. According to the present invention, the secretory expression of the canine recombinant interferon-alpha3 in the pichia pastoris is achieved, the canine recombinant interferon-alpha3 with efficient antiviral activity is obtained, and the antiviral activity of the canine recombinant interferon-alpha3 is improved by optimizing the pichia pastoris expression system.

This invention discloses a kit for detecting α-interferon and related applications, relating to the biological field. The kit includes a capture protein for capturing α-interferon and a detection protein for detecting α-interferon; the capture protein includes an α-interferon receptor protein; the detection protein includes an antibody against α-interferon. This kit is applied to IFN-α detection, covering multiple IFN-α subtypes, including natural and recombinant interferon, and exhibits no cross-reactivity with INF-β and INF-ε. It has high detection accuracy and good repeatability, enabling rapid and effective detection of IFN-α levels in human serum, thereby more accurately reflecting the overall level and activity status of IFN-α in the body. This is of great significance for understanding human immune status, diagnosing and monitoring disease development, and evaluating the effectiveness of treatment.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and / or preventing postoperative tumor recurrence and / or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and / or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

The invention discloses a cat omega interferon RNA vaccine and application thereof, and relates to the technical field of veterinary biological products. After the optimized cat omega interferon is used for immunizing an experimental animal, virus replication can be inhibited, so that the effect of protecting the body is achieved. Therefore, the nucleic acid molecule provided by the invention can be used for developing recombinant protein vaccines or preparing nucleic acid vaccines. Compared with the recombinant interferon protein on the market, the vaccine provided by the invention has the capability of enhancing the neutralizing antibody level of various vaccines, and can efficiently reduce the virus titer, interfere the combination of the virus and a host cell receptor and inhibit the replication of the virus, thereby playing a role in protecting the body and promoting the antiviral capability of the body.